



## State-of-the-Art Cancer Biology and Therapeutics in Poland

Guest Editor:

**Dr. Anna Mucha-Matecka**

Department of Radiotherapy,  
Maria Skłodowska-Curie National  
Research Institute of Oncology,  
Cracow Branch, Garncarska 11,  
31-115 Cracow, Poland

Deadline for manuscript  
submissions:

**closed (31 January 2023)**

### Message from the Guest Editor

Dear Colleagues,

All over the world, including in Poland, there is ongoing progress in the biology and therapy of malignant neoplasms. In 2017, according to the National Cancer Registry, 164,875 new cases of malignant neoplasms were reported in Poland. Thanks to novel treatment methods, cancer is, in many cases, becoming a chronic condition rather than a fatal disease. Contemporary oncology has a wide arsenal of drugs and therapeutic procedures aimed at eradicating neoplastic cells. Modern cancer treatment is based on the concept of an interdisciplinary and holistic approach to cancer therapy. The development of basic sciences in Poland (radiobiology and molecular biology) allows for the identification and verification of new molecular biomarkers.

I invite you to share your results in the field of biology and treatment of malignant neoplasms in your centers in Poland in this Special Issue of *Biomedicines*.

Dr. Anna Mucha-Matecka  
*Guest Editor*





an Open Access Journal by MDPI

## Editor-in-Chief

### Prof. Dr. Felipe Fregni

1. Neuromodulation Center and  
Center for Clinical Research  
Learning, Spaulding  
Rehabilitation Hospital and  
Massachusetts General Hospital,  
Harvard Medical School, Boston,  
MA 02114, USA  
2. Department of Epidemiology,  
Harvard T.H. Chan School of  
Public Health, Boston, MA 02115,  
USA

## Message from the Editor-in-Chief

*Biomedicines* (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

## Author Benefits

**Open Access:** free for readers, with [article processing charges \(APC\)](#) paid by authors or their institutions.

**High Visibility:** indexed within [Scopus](#), [SCIE \(Web of Science\)](#), [PubMed](#), [PMC](#), [CAPUS / SciFinder](#), and [other databases](#).

**Journal Rank:** JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

## Contact Us

*Biomedicines* Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland

Tel: +41 61 683 77 34  
[www.mdpi.com](http://www.mdpi.com)

[mdpi.com/journal/biomedicines](http://mdpi.com/journal/biomedicines)  
[biomedicines@mdpi.com](mailto:biomedicines@mdpi.com)  
[X@Biomed\\_MDPI](#)